Smith & NephewSNN +2.20%86 ROA % is 6.28% as of Dec. 2025, which is 18% above its 10-year median of 5.32. GuruFocus rates SNN with a GF Score™ of 86/100 and a GF Value™ of $31.44 (Fairly Valued). The stock has 3 warning signs investors should review. Among 857 Medical Devices & Instruments companies, Smith & Nephew ranks better than 73.16% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Smith & Nephew's annualizedNet Income for the quarter that ended in Dec. 2025 was $664 Mil.
Smith & Nephew's average Total Assets over the quarter that ended in Dec. 2025 was $10,575 Mil. Therefore, Smith & Nephew's annualized ROA % for the quarter that ended in Dec. 2025 was 6.28%.
The historical rank and industry rank for Smith & Nephew's ROA % or its related term are showing as below:
SNN'
s ROA % Range Over the Past 10 Years
Min: 2.23 Med: 5.32 Max: 11.77
Current: 5.83
During the past 13 years, Smith & Nephew's highest ROA % was 11.77%. The lowest was 2.23%. And the median was 5.32%.
SNN's ROA % is ranked better than 73.16% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.59
vs SNN: 5.83
Smith & Nephew (NYSE:SNN) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Smith & Nephew ROA % Related Terms
Smith & Nephew ROA % Historical Data
* Premium members only.
The historical data trend for Smith & Nephew's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Smith & Nephew's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Smith & Nephew ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Smith & Nephew's ROA % distribution charts can be found below:
* The bar in red indicates where Smith & Nephew's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Smith & Nephew (SNN) has a ROA % of 6.28% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Smith & Nephew and its competitors. This is 18% above median its historical median of 5.32. Over the past decade, Smith & Nephew's ROA % has ranged from 2.23 to 11.77. According to the industry distribution chart, Smith & Nephew ranks #230 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 26.8%.
Is Smith & Nephew's ROA % too high?
Smith & Nephew's current ROA % of 6.28% is 18% above median its 10-year median of 5.32. Over the past 10 years, this metric has ranged from a low of 2.23 to a high of 11.77. The Medical Devices & Instruments industry median ROA % is 0.59. Smith & Nephew's value of 6.28% is 964.4% above this industry median. Based on the distribution chart, Smith & Nephew ranks #230 out of 857 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Smith & Nephew has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Smith & Nephew's ROA % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Smith & Nephew ranks #230 out of 857 companies for ROA %. This puts Smith & Nephew in the upper half of its industry. The industry median ROA % is 0.59. Smith & Nephew's value of 6.28% is 964.4% above this benchmark. Historically, Smith & Nephew's own ROA % has ranged from 2.23 to 11.77 over the past decade. While the company's 10-year median is 5.32 vs. the industry median of 0.59, Smith & Nephew has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.59, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Smith & Nephew's current ROA % of 6.28% is 964.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Smith & Nephew and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Smith & Nephew's current ROA % is 6.28%, which is 18% above median its own 10-year median of 5.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Smith & Nephew stock overvalued right now?
Based on GuruFocus' analysis, Smith & Nephew (SNN) is currently considered Fairly Valued. The stock's GF Value™ is $31.44, compared to a current price of $30.26 — trading 3.8% below its estimated fair value. The current ROA % is 6.28%, which is 18% above median its 10-year median of 5.32 and 964.4% above the Medical Devices & Instruments industry median of 0.59. Smith & Nephew's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Smith & Nephew (SNN), the current ROA % is 6.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Smith & Nephew (SNN) Overvalued in 2026?
Based on GuruFocus' analysis, Smith & Nephew stock appears to be undervalued.
The current stock price of $30.26 is trading 3.8% below its estimated GF Value™ of $31.44.
GuruFocus considers Smith & Nephew to be Fairly Valued.
Key valuation signals for SNN:
ROA %: 6.28% (18% above median its 10-year median of 5.32)
GF Value™: $31.44 vs. price of $30.26 (3.8% below fair value)
Industry Position: 964.4% above the Medical Devices & Instruments median (#230 of 857)
No single metric tells the full story. See the SNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
86GF Score
Get the complete analysis for SNN
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNN has been successfully added to your 
